Grants and Contributions:
Title:
COVID-19 VI Providence
Agreement Number:
957288
Agreement Value:
$6,400,000.00
Agreement Date:
Sep 1, 2020 - Jul 30, 2021
Description:
Providence Therapeutics, Canada’s leading mRNA vaccine manufacture, is manufacturing an mRNA vaccine against COVID-19. The company is in the R&D phases to demonstrate the preclinical and clinical efficacy of PTX-COVID19-B.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Calgary, Alberta, CA T2Z 3P4
Reference Number:
172-2020-2021-Q3-957288
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
738045079
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 30 days.
Amendment Date
Jul 5, 2021
Recipient's Legal Name:
Providence Therapeutics Holdings Inc.
Federal Riding Name:
Calgary Shepard
Federal Riding Number:
48011
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254
Amendments: